Ann: December Quarterly Activities Report, page-80

First 80 Last

Share
Profile

Follow
PatienceToWin

12,915 Posts.

1006

11/02/22

09:41

Post #: 59502668
Share

Originally posted by savvyinvestor ↑

Numbers look good to me, especially the pricing guidance for next quarter which beat my expectations given past history.

will continue holding as one of my biggest positions at an average of $3, awaiting the $20 party and beyond. This may be a good stock for a multi decade hold to let it compound whilst they build out their portfolio of assets and expand each into its 2nd and 3rd stages etc.

will have its ups and downs, but a nice diversified group tier 1 lowest quartile of cost curve assets, so should be able to ride the waves of the lithium cycle.

I think there is a fair chance we will hit $15 later this year as the fomo builds from both retail and institutions, especially now that ake is inside the asx100 and I suspect is widely under owned by the fund managers and super funds...they will have to accumulate some AKE to track the index.

Expand

News from a few weeks back is a sound reminder where the SP is heading later this year.

AKE – Credit Suisse rates the stock as Outperform

By Broker News | More Articles by Broker News
MORE ALLKEM LIMITED CONTENT

Credit Suisse has issued another spodumene price increase through to 2023, noting Allkem suggests further upside risk to the broker’s forecasts given high spot pricing.
With a cheaper priced contract set to complete in the June quarter, the broker expects Allkem prices to accelerate towards record spot prices in the December half. Elsewhere, covid impacts have pushed the Sal de Vida startup back six months to the first half of 2023.
The Outperform rating is retained and the target price increases to $13.70 from $13.20.

AKE Price at posting: $9.90 Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply